Ratings Bumrungrad Hospital

Equities

BH

TH0168A10Z01

End-of-day quote Thailand S.E. Other stock markets 06:00:00 2024-05-13 pm EDT			5-day change	1st Jan Change
256 ^THB	-0.78%		+1.59%	+15.32%

May. 02	Transcript : Bumrungrad Hospital Public Company Limited, Q1 2024 Earnings Call, May 02, 2024
Apr. 25	Bumrungrad Hospital Public Company Limited Approves Dividend for an Operating Period from 1 July 2023 to 31 December 2023, Payable on 10 May 2024	CI

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The opinion of analysts covering the stock has improved over the past four months.
Over the past twelve months, analysts' opinions have been strongly revised upwards.
Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

The company's earnings growth outlook lacks momentum and is a weakness.
The company benefits from high valuations in earnings multiples.
The company's "enterprise value to sales" ratio is among the highest in the world.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	ESG Refinitiv
BUMRUNGRAD HOSPITAL	+15.32%	5.56B	B
CVS HEALTH CORPORATION	-29.08%	70.3B	B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+2.04%	27.46B	C+
LABORATORY CORPORATION OF AMERICA HOLDINGS	-7.08%	17.8B	B
FRESENIUS SE & CO. KGAA	+2.21%	17.46B	A-
QUEST DIAGNOSTICS INCORPORATED	+0.93%	15.46B	A-
REDE D'OR SÃO LUIZ S.A.	+6.78%	13.49B	B-
FRESENIUS MEDICAL CARE AG	+8.80%	13.06B	A-
NATERA, INC.	+68.45%	12.96B	C-
TENET HEALTHCARE CORPORATION	+70.12%	12.56B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes